Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101

Creative Medical Technology Holdings, Inc. (CELZ) announced that the FDA has granted an Orphan Drug designation to its cell-based immunotherapy, CELZ-101, also known as ImmCelz.CELZ-101 is being developed for the prevention of allograft rejection in patients undergoing pancreatic islet cell transplantation for the treatment of type 1 diabetes.Type 1 diabetes is marked by extreme fluctuations in blood glucose levels.The perquisites that come from Orphan Drug designation include assistance in the drug develop ...